Similarly, a phase Ib/II study (NCT01870726, https://clinicaltrials.gov/study/NCT01870726, accessed on 27 October 2024) comparing the efficacy of INC280 (capmatinib), a MET inhibitor, alone with its combination with buparlisib in adult patients with recurrent glioblastoma showed no clear activity using the combination, despite the described synergy in preclinical glioblastoma models [166]. The gene discussed is MET; the disease is glioblastoma.